Respiratory Medicine
Volume 105, Issue 3 , Pages 506-510 , March 2011

The cyclooxygenase-2-765C promoter polymorphism protects against the development of chronic obstructive pulmonary disease

This Paper is dedicated to our close friend and mentor Professor Peter Black who died suddenly in January 2010. Peter was instrumental in the conception and design of this study. His death is a huge loss to the COPD research community and to us personally.

  • Lian Wu

      Affiliations

    • Department of Pharmacology & Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    • Corresponding Author InformationCorresponding author. Tel.: +64 9 3737599x86023; fax: +64 9 3737556.
    • ,
  • Mervyn Merrilees

      Affiliations

    • Department of Anatomy with Radiology, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    • ,
  • Robert P. Young

      Affiliations

    • Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    • ,
  • Peter N. Black

      Affiliations

    • Department of Pharmacology & Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand

Received 31 May 2010 ,Accepted 3 August 2010.

References 

  1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–946
  2. Sandford AJ, Weir TD, Pare PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J. 1997;10:1380–1391
  3. Hersh CP, Demeo DL, Lange C, Litonjua AA, Reilly JJ, Kwiatowski D, et al. Attampted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol. 2005;33:71–78
  4. Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov. 2006;5:75–86
  5. Xaubet A, Roca-Ferrer J, Pujols L, Ramirez J, Mullol J, Marin-Arguedas A, et al. Cyclooxygenase-2 is upregulated in lung parenchyma of chronic obstructive pulmonary disease and down regulated in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:35–42
  6. Taha R, Olivenstein R, Utsumi T, Ernst P, Barnes PJ, Rodger IW, et al. Prostaglandin H synthase 2 expression in airway cells from patients with asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:636–640
  7. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloprotienases. Cancer Res. 2000;60:4629–4637
  8. Rennard S. Chronic obstructive pulmonary disease. Linking outcomes and pathobiology of disease modification. Proc Am Thorac Soc. 2006;3:276–280
  9. Lama V, Moore BB, Christensen P, Toews GB, Peters-Golden M. Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent. Am J Respir Cell Mol Biol. 2002;27:752–758
  10. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of a role in acute phase inflammatory response. Arterioscler Thromb Vasc Biol. 2002;22:1631–1636
  11. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, et al. A polymorphism in the cyclooxygenase-2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA. 2004;291:2221–2228
  12. Sandford AJ, et al. 1-antitrypsin genotypes and the acute phase response to open heart surgery. Am J Respir Crit Care Med. 1999;159:1624–1628
  13. Pritchard JK, Stephens M, Donnelly P. Inference of population structure from multilocus genotype data. Genetics. 2000;155:945–959
  14. Ohnishi K, et al. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest. 1998;78:1077–1087
  15. Segura-Valdez L, et al. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest. 2000;117:684–694
  16. Finlay GA, O’Donnell MD, O’Connor CM, Hayes JP, FitzGerald MX. Elastin and collagen remodelling in emphysema. A scanning electron microscopy study. Am J Pathol. 1996;149:1405–1415
  17. Yao M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res. 2003;63:586–592
  18. Holz O, Zuhlke I, Jaksztat E, et al. Lung fibroblasts from patients with emphysema show a reduced proliferation rate in culture. Eur Respir J. 2004;24:575–579
  19. Wu L, Chau J, Young RP, Pokorny V, Mills GD, Hopkins R, et al. Transforming growth factor–β1 genotype and susceptibility to chronic obstructive pulmonary disease. Thorax. 2004;59:126–129
  20. Ogawa K, Chen F, Kuang C, Chen Y. Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-beta is mediated by a nuclear factor-kappaB site. Biochem J. 2004;381(Pt 2):413–422
  21. Hetzel M, Bachem M, Anders D, Trischler G, Faehling M. Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts. Lung. 2005;183:225–237
  22. Young RP, Hopkins R, Black PN, Eddy C, Wu L, Gamble GD, et al. Functional variants of antioxidant genes in smokers with COPD and in those with normal lung function. Thorax. 2006 May;61(5):394–399Epub 2006 Feb 7. PubMed PMID: 16467073; PubMed Central PMCID: PMC2111196
  23. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet. 2003;361:598–604
  24. Smolonska J, Wijmenga C, Postma DS, Boezen HM. Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years’ research. Am J Respir Crit Care Med. 2009 Oct 1;180(7):618–631Epub 2009 Jul 16. Review. Erratum in: Am J Respir Crit Care Med. 2010 Apr 1;181(7):765. PubMed PMID:19608716
  25. Ulrich CM, Whitton J, Yu J-H, Sibert J, Sparks R, Potter JD, et al. PTGS2 (Cox-2) -765G>C promoter variant reduces the risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev. 2005;14:616–619

PII: S0954-6111(10)00346-X

doi: 10.1016/j.rmed.2010.08.002

Respiratory Medicine
Volume 105, Issue 3 , Pages 506-510 , March 2011

Article Tools